Oversight of Agency Efforts to Prevent and Treat Drug Abuse

Oversight of Agency Efforts to Prevent and Treat Drug Abuse
Author: United States House of Representatives
Publisher:
Total Pages: 109
Release: 2020-03-05
Genre:
ISBN:

Oversight of agency efforts to prevent and treat drug abuse : hearing before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session,

TIP 35: Enhancing Motivation for Change in Substance Use Disorder Treatment (Updated 2019)

TIP 35: Enhancing Motivation for Change in Substance Use Disorder Treatment (Updated 2019)
Author: U.S. Department of Health and Human Services
Publisher: Lulu.com
Total Pages: 208
Release: 2019-11-19
Genre: Reference
ISBN: 1794755136

Motivation is key to substance use behavior change. Counselors can support clients' movement toward positive changes in their substance use by identifying and enhancing motivation that already exists. Motivational approaches are based on the principles of person-centered counseling. Counselors' use of empathy, not authority and power, is key to enhancing clients' motivation to change. Clients are experts in their own recovery from SUDs. Counselors should engage them in collaborative partnerships. Ambivalence about change is normal. Resistance to change is an expression of ambivalence about change, not a client trait or characteristic. Confrontational approaches increase client resistance and discord in the counseling relationship. Motivational approaches explore ambivalence in a nonjudgmental and compassionate way.

Food and Drug Administration Advisory Committees

Food and Drug Administration Advisory Committees
Author: Institute of Medicine
Publisher: National Academies Press
Total Pages: 239
Release: 1992-02-01
Genre: Medical
ISBN: 0309048370

Like many other agencies of the federal government, the Food and Drug Administration (FDA) relies extensively on external advisory committees for independent scientific and technical advice. Recognizing that the existing advisory committee system is essentially sound, this volume recommends ways of enhancing the use of these committees in the evaluation of drugs, biological materials, and medical devices; strengthening the agency's management of the system; and increasing the accountability of the system to the public. In doing so, it examines and makes recommendations on such issues as the recruitment of committee members, the FDA's management of financial conflict of interest and intellectual bias among members, and the operations and management of the advisory committee system.